Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

852A

Drug Profile

852A

Alternative Names: 3M-852A; 852; PF-04878691; PF-4878691; S-32865

Latest Information Update: 14 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3M Drug Delivery Systems
  • Developer Kindeva Drug Delivery; Masonic Cancer Center; Pfizer
  • Class Amines; Antineoplastics; Antivirals; Imidazoles; Quinolines; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Skin disorders
  • Discontinued Barrett's oesophagus; Haematological malignancies; Hepatitis C; Malignant melanoma; Solid tumours

Most Recent Events

  • 28 May 2019 No recent reports of development identified for phase-I development in Skin-disorders in USA (Topical)
  • 29 Apr 2016 Chemical structure information added
  • 26 Apr 2016 852 is available for licensing as of 26 Apr 2016. http://www.3m.com/3M/en_US/drug-delivery-systems-us/
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top